Dan Thomas, GSK
Written by Jackie Howard Tuesday, 08 May 2012 11:04
Daniel Thomas is a Senior Investigator on secondment to the Screening and Compound Profiling Department from the Biological Reagents and Assay Development Department at GlaxoSmithKline Pharmaceuticals. He received both his BSc and Ph.D. in Medical Biochemistry from the University of Leeds (2001 and 2005). He joined Glaxo Wellcome as an industrial placement student (1999) and returned as a Ph.D. student (2002-2004), where he was involved in research that focused on identifying and characterizing peptide and protein substrates of the cysteine protease, calpain-2. In 2005, he joined the Enzymology group at GlaxoSmithKline Pharmaceuticals, where he has gained significant experience working within early stage small molecule drug discovery research. He has an extensive theoretical and practical knowledge of biochemical assay development and transient/steady-state enzyme kinetics in multiple formats for HTS, SAR, fragment and Mode of Action screening efforts. He currently leads a team providing SAR support and focused single shot screening for project teams run locally and trans-nationally across a broad range of therapeutic areas, including respiratory, cardiovascular and immuno-inflammation. In addition, he is responsible for managing a portfolio of over 30 catalytic enzyme assays (resourcing, performance, metrics and as an enzymology mentor), providing detailed mechanistic support and guidance in the detailed characterisation of target-substrate and target-compound interactions and more recently co-leading a neurodegeneration programme. He has also led the extended evaluation and internalization of the HP picoliter dispense technology focusing on its applications within drug discovery.